Key result
Elevated Castelli's risk index linked to ~2.1-fold higher major cardiovascular events risk after PCI for ACS.
Why the study?
There are no studies on the prognostic value of Castelli's risk indices-I and II in patients with ACS undergoing PCI.
Do elevated Castelli's risk indices (CRI-I and CRI-II) predict an increased risk of major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Cohort (n=1,475)
No
Do elevated Castelli's risk indices (CRI-I and CRI-II) predict an increased risk of major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Castelli's risk indices (CRI-I and CRI-II) can serve as independent, easily calculable predictors of major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention, improving prognostic risk stratification.
BACKGROUND AND AIMS: Composite lipid indices are closely related to the risk and poor prognosis of diseases. However, there are no studies on the prognostic value of Castelli's risk indices-I and II (CRI-I, CRI-II) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Therefore, the aim of this study was to investigate the association of CRI-I and CRI-II with the prognosis of patients with ACS undergoing PCI. PATIENTS AND METHODS: A total of 1475 patients with ACS undergoing PCI were consecutively enrolled in this prospective cohort study from January 2016 to December 2018. The CRI-I and CRI-II were measured. The endpoints were MACEs, including all-cause mortality, requirement of rehospitalization for severe heart failure, recurrence of myocardial infarction, in-stent restenosis, and reaccept PCI. Follow-up data were collected via clinical visits or telephone calls at 1, 3, 6, and 12 months and annually thereafter. RESULT: Multivariable Cox regression analysis revealed that the risk of MACEs increased gradually with increasing CRI-I and CRI-II. The cumulative survival rate in the CRI-I ≥ 3.350 and CRI-II ≥ 1.697 groups was significantly lower than that in the CRI-I < 3.350 and CRI-II < 1.697 groups, respectively (log-rank tests: all p < 0.001). The nomogram demonstrated good predictive performance for the 1-, 2-, and 3-year survival probability. CONCLUSIONS: CRI-I ≥ 3.350 and CRI-II ≥ 1.697 could serve as independent predictors of MACEs in patients with ACS undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cohort in Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (n=1,475). High Castelli's risk index-I (CRI-I ≥ 3.350) and CRI-II (≥ 1.697) vs. Low Castelli's risk index-I and II was evaluated on Major adverse cardiovascular events (MACEs) including all-cause mortality, rehospitalization for severe heart failure, recurrence of myocardial infarction, in-stent restenosis, and repeat PCI (HR 2.065, 95% CI 1.314-3.244, p=0.002). Higher Castelli's risk index-I and II levels were independently associated with an increased risk of major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: